Saturday 17 October 2026
Export TMCI’s income statement to Excel — free account
Treace Medical Concepts, Inc.
TMCI Healthcare Medical Devices
Treace Medical Concepts, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $212.7 million, up 1.59% from fiscal 2024. In the quarter to June 2026, revenue fell 4.24%, EPS grew 14.3%, free cash flow grew 11.7% and total debt rose 4.84%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
3.87
0.25
−6.07%
Follow TMCI
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
2 | 2 | 2 | 3 |
+8 more TTM periods Free account |
| (71.99%) | (66.88%) | (58.94%) | (51.63%) | ||
| (30.72%) | (31.31%) | (28.95%) | (24.47%) | ||
ROIC |
(42.96%) | (42.93%) | (35.80%) | (35.49%) | |
Return on Tangible Assets |
(53.40%) | (50.43%) | (44.98%) | (39.44%) | |
Average Days of Receivables |
51.08 | 53.45 | 72.34 | 54.96 | |
Free Cash Flow per Share |
(0.38) | (0.40) | (0.47) | (0.41) | |
Free Cash Flow |
(25.05) | (25.96) | (29.49) | (26.34) | |
Capital Expenditures |
(10.47) | (13.04) | (13.52) | (14.19) | |
| Other line items | |||||
Cash ROIC |
(14.79%) | (14.04%) | (15.42%) | (13.16%) | |
Accounts Receivable Turnover |
6.95 | 6.75 | 5.13 | 7.66 | |
Accounts Payable Turnover |
2.34 | 3.14 | 4.98 | 2.54 | |
Inventory Turnover |
1.03 | 1.13 | 1.14 | 1.04 | |
Average Days of Payables |
138.96 | 117.50 | 57.18 | 133.43 | |
Days of Inventory on Hand |
342.12 | 315.65 | 306.29 | 343.23 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
8.87% | 9.33% | 9.54% | 9.57% | |
Selling, General and Administrative Expense of Revenue |
96.74% | 97.27% | 95.74% | 92.43% | |
Share Based Compensation of Revenue |
14.64% | 16.00% | 15.90% | 15.91% | |
Interest Coverage |
(9.23) | (9.99) | (10.18) | (9.17) | |
Operating CF/Net income |
0.24 | 0.21 | 0.27 | 0.24 | |
Depreciation/Fixed assets |
0.28 | 0.30 | 0.36 | 0.33 | |
Capex/Depreciation |
(1.16) | (1.37) | (1.25) | (1.42) | |
Revenue per Share |
3.16 | 3.21 | 3.36 | 3.45 | |
Operating CF per Share |
(0.22) | (0.20) | (0.25) | (0.19) | |
Capex per Share |
(0.16) | (0.20) | (0.21) | (0.22) | |
Capex to Sales |
0.05 | 0.06 | 0.06 | 0.06 |
Columns are period end dates